Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity
Kratz, J. D.; Rehman, S.; Johnson, K. A.; Gillette, A. A.; Sunil, A.; Favreau, P. F.; Pasch, C. A.; Miller, D.; Zarling, L. C.; Yeung, A. H.; Clipson, L.; Anderson, S. J.; DeZeeuw, A. K.; Sprackling, C. M.; Lemmon, K. K.; Abbott, D. E.; Burkard, M. E.; Bassetti, M. F.; Eickhoff, J. C.; Foley, E. F.; Heise, C. P.; Kimple, R. J.; Lawson, E. H.; LoConte, N. K.; Lubner, S. J.; Mulkerin, D. K.; Matkowskyj, K. A.; Sanger, C. B.; Uboha, N. V.; Mcilwain, S. J.; Ong, I. M.; Carchman, E. H.; Skala, M. C.; Deming, D. A.
Show abstract
Tumor heterogeneity is predicted to confer inferior clinical outcomes, however modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technologies are limited in their ability to identify rare subclonal populations and predict response to the multitude of available treatments for patients. Patient-derived organotypic cultures have significantly improved the modeling of cancer biology by faithfully representing the molecular features of primary malignant tissues. Patient-derived cancer organoid (PCO) cultures contain numerous individual organoids with the potential to recapitulate heterogeneity, though PCOs are most commonly studied in bulk ignoring any diversity in the molecular profile or treatment response. Here we demonstrate the advantage of evaluating individual PCOs in conjunction with cellular level optical metabolic imaging to characterize the largely ignored heterogeneity within these cultures to predict clinical therapeutic response, identify subclonal populations, and determine patient specific mechanisms of resistance.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.